Login to Your Account



Alcon Paying Up to $589M for EsbaTech Eye Business

By Cormac Sheridan


Wednesday, September 16, 2009
Underlining the current vogue for antibody-based technologies, Alcon Inc. is acquiring the ophthalmology business of ESBATech AG for $150 million in cash plus up to $439 million in potential milestones. (BioWorld International)

To continue reading subscribe now to BioWorld Asia (formerly International)

Learn More about BioWorld Asia (formerly International)

Already a subscriber? Sign In or Buy now to activate your subscription